|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.880 USD | -0.15% |
|
+6.96% | -2.98% |
| 05-23 | Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025 | |
| 05-19 | Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder | RE |
Transcripts
Search
05-23 | ||
03-13 | ||
02-27 | ||
11-13 | ||
11-12 | ||
24-08-08 | ||
24-06-12 | ||
24-05-23 | ||
24-05-09 | ||
24-04-02 | ||
24-03-27 | ||
23-12-01 | ||
23-11-07 | ||
23-09-13 | ||
23-08-10 | ||
23-06-14 | ||
23-05-11 | ||
23-03-21 | ||
23-02-28 | ||
22-12-20 | ||
22-11-10 | ||
22-09-14 | ||
22-08-11 | ||
22-05-12 | ||
22-03-16 |
No results for this search
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Transcripts
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition